Live search
TopFind is fetching the latest matches for your search.
We reviewed 89 live results for bevacizumab biosimilar and narrowed them down to the 3 options that look most worth comparing first.
The strongest themes across this short list are Oncology and Biosimilar.
Sumber: Biocon Biologics Philippines Inc.
Deskripsi
An oncology biosimilar used in the treatment of various solid tumors, expanding therapeutic options for cancer patients.
Paling cocok untuk
solid tumor treatment, cancer therapy and oncology clinics
Tag
Penilaian
Sumber: Amgen
Deskripsi
Mvasi is a biosimilar to the reference drug Avastin, containing the active substance bevacizumab. This oncology treatment is administered as an intravenous infusion to patients with metastatic colorectal cancer, non-squamous non-small cell lung cancer, glioblastoma, and other advanced cancers. In Malaysia, it is registered under MAL19086005ACZ and is supplied in 100 mg and 400 mg vials as a concentrate for solution. As a biosimilar, it provides a highly similar clinical profile to its reference product, supporting cancer management and therapy accessibility.
Paling cocok untuk
metastatic colorectal cancer, non-small cell lung cancer patients, biosimilar treatment options, intravenous oncology therapy and hospital-based cancer care
Penilaian
Sumber: Amgen
Deskripsi
Mvasi is a biosimilar monoclonal antibody and VEGF inhibitor used in oncology to treat various forms of cancer, including metastatic colorectal cancer (mCRC), non-small cell lung cancer (NSCLC), glioblastoma, and metastatic breast or cervical cancer. It is available as a concentrate for solution for infusion in 100 mg/4 mL and 400 mg/16 mL single-use vials. In Singapore, it is registered with the HSA and listed on the MOH Standard Drug List, providing patients with access to government subsidies and MediShield Life claims for cancer treatment.
Paling cocok untuk
Oncology patients, Metastatic cancer treatment and Subsidized medical care
Penilaian
| Bandingkan | Bevacizumab Biosimilar | Mvasi (bevacizumab) | Mvasi (bevacizumab) |
|---|---|---|---|
| Sumber | Biocon Biologics Philippines Inc. | Amgen | Amgen |
| Deskripsi | An oncology biosimilar used in the treatment of various solid tumors, expanding therapeutic options for cancer patients. | Mvasi is a biosimilar to the reference drug Avastin, containing the active substance bevacizumab. This oncology treatment is administered as an intravenous infusion to patients with metastatic colorectal cancer, non-squamous non-small cell lung cancer, glioblastoma, and other advanced cancers. In Malaysia, it is registered under MAL19086005ACZ and is supplied in 100 mg and 400 mg vials as a concentrate for solution. As a biosimilar, it provides a highly similar clinical profile to its reference product, supporting cancer management and therapy accessibility. | Mvasi is a biosimilar monoclonal antibody and VEGF inhibitor used in oncology to treat various forms of cancer, including metastatic colorectal cancer (mCRC), non-small cell lung cancer (NSCLC), glioblastoma, and metastatic breast or cervical cancer. It is available as a concentrate for solution for infusion in 100 mg/4 mL and 400 mg/16 mL single-use vials. In Singapore, it is registered with the HSA and listed on the MOH Standard Drug List, providing patients with access to government subsidies and MediShield Life claims for cancer treatment. |
| Paling cocok untuk | solid tumor treatment, cancer therapy and oncology clinics | metastatic colorectal cancer, non-small cell lung cancer patients, biosimilar treatment options, intravenous oncology therapy and hospital-based cancer care | Oncology patients, Metastatic cancer treatment and Subsidized medical care |
| Tag | |||
| Aksi | Lihat detail | Lihat detail | Lihat detail |
| Penilaian |
Jika Anda ingin memulai dari opsi yang paling seimbang, saya merekomendasikan:
"Bevacizumab Biosimilar from Biocon Biologics Philippines Inc.."
Saya memilih ini karena It serves as an essential biosimilar for treating diverse solid tumor types in cancer care.